Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-05-12T08:31:11.729Z Has data issue: false hasContentIssue false
  • English
  • Français

Intracellular expression profile and clinical significance of the CCR9–CCL25 chemokine receptor complex in nasopharyngeal carcinoma

Published online by Cambridge University Press:  17 August 2015

L-F Ye ,
J Huang ,
L-P Zhang  and
Z Chen
L-F Ye*
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, China
J Huang
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, China
L-P Zhang
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, China
Z Chen
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, China
*
Address for correspondence: Dr L-F Ye, Department of Otolaryngology Head and Neck Surgery, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, China. E-mail: yelinfeng69@163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

This study aimed to investigate the association of C-C chemokine receptor type 9 (CCR9) and C-C motif chemokine 25 (CCL25) expression levels with clinical and tumour–node–metastasis stage in nasopharyngeal carcinoma.

Methods:

A total of 42 nasopharyngeal carcinoma patients (nasopharyngeal carcinoma group) and 18 patients with a normal nasopharynx (control group) were included in this study. Tissues were collected during surgery and medical examinations. The CCR9 and CCL25 messenger RNA and protein levels were measured using quantitative reverse transcription polymerase chain reaction, Western blotting and immunohistochemical analysis.

Results:

CCR9 and CCL25 messenger RNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group (p < 0.05). Both CCR9 and CCL25 messenger RNA and protein levels were significantly higher in advanced-stage nasopharyngeal carcinoma (stages III and IV) patients compared with early-stage nasopharyngeal carcinoma (stages I and II) patients (p < 0.05).

Conclusion:

The extent of CCR9 and CCL25 upregulation in nasopharyngeal carcinoma correlates with the tumour–node–metastasis stage.

Keywords

Nasopharyngeal NeoplasmsChemokines, CC
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 129 , Issue 10 , October 2015 , pp. 1013 - 1019
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Lee, AW, Poon, YF, Foo, W, Law, SC, Cheung, FK, Chan, DK et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261–70CrossRefGoogle ScholarPubMed
2Ahmad, A, Stefani, S. Distant metastases of nasopharyngeal carcinoma. A study of 256 male patients. J Surg Oncol 1986;33:194–7CrossRefGoogle ScholarPubMed
3Cho, WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1–3CrossRefGoogle ScholarPubMed
4Glastonbury, CM. Nasopharyngeal carcinoma: the role of magnetic resonance imaging in diagnosis, staging, treatment, and follow-up. Top Magn Reson Imaging 2007;18:225–35CrossRefGoogle ScholarPubMed
5Balkwill, F. Cancer and the chemokine network. Nature 2004;4:540–50Google ScholarPubMed
6Papadakis, KA, Prehn, J, Nelson, V, Cheng, L, Binder, SW, Ponath, PD et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000;165:5069–76CrossRefGoogle ScholarPubMed
7Wright, DE, Bowman, EP, Wagers, AJ, Butcher, EC, Weissman, IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002;195:1145–54CrossRefGoogle ScholarPubMed
8Zaballos, A, Gutiérrez, J, Varona, R, Ardavín, C, Márquez, G. Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 1999;162:5671–5CrossRefGoogle ScholarPubMed
9Svensson, M, Marsal, J, Ericsson, A, Carramolino, L, Brodén, T, Márquez, G et al. CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa. J Clin Invest 2002;110:1113–21CrossRefGoogle Scholar
10Eksteen, B, Grant, AJ, Miles, A, Curbishley, SM, Lalor, PF, Hübscher, SG et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200:1511–17CrossRefGoogle Scholar
11Connor, SJ, Paraskevopoulos, N, Newman, R, Cuan, N, Hampartzoumian, T, Lloyd, AR et al. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 2004;53:1287–94CrossRefGoogle Scholar
12Hieshima, K, Kawasaki, Y, Hanamoto, H, Nakayama, T, Nagakubo, D, Kanamaru, A et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 2004;173:3668–75CrossRefGoogle ScholarPubMed
13Annels, NE, Willemze, AJ, van der Velden, VH, Faaij, CM, van Wering, E, Sie-Go, DM et al. Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL. Blood 2004;103:2806–8CrossRefGoogle Scholar
14Sobin, LH, Wittekind, C, eds. International Union Against Cancer. TNM Classification of Malignant Tumours, 6th edn. Hoboken: John Wiley & Sons, 2002Google Scholar
15Balkwill, F, Mantovani, A. Inflammation and cancer: back to Virchow. Lancet 2001;357:539–45CrossRefGoogle ScholarPubMed
16Brigati, C, Noonan, DM, Albini, A, Benelli, R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19:247–58CrossRefGoogle ScholarPubMed
17Coussens, LM, Werb, Z. Cancer and inflammation. Nature 2002;420:860–7CrossRefGoogle Scholar
18Negus, RP, Stamp, GW, Hadley, J, Balkwill, FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-Cchemokines. Am J Pathol 1997;150:1723–34Google Scholar
19Pollard, JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8CrossRefGoogle ScholarPubMed
20Balkwill, F. Chemokine biology in cancer. Semin Immunol 2003;15:49–55CrossRefGoogle ScholarPubMed
21Kidd, S, Caldwell, L, Dietrich, M, Samudio, I, Spaeth, EL, Watson, K, Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010;12:615–25CrossRefGoogle ScholarPubMed
22Balkwill, F, Mantovani, A. Inflammation and cancer: back to Virchow. Lancet 2001;357:539–45CrossRefGoogle ScholarPubMed
23Bottazzi, B, Polentarutti, N, Acero, R, Balsari, A, Boraschi, D, Ghezzi, P et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983;220:210–12CrossRefGoogle ScholarPubMed
24Dhawan, P, Richmond, A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002;72:9–18CrossRefGoogle ScholarPubMed
25Hu, Y, Zhang, L, Wu, R, Han, R, Jia, Y, Jiang, Z et al. Specific killing of CCR9 high-expressing acute T lymphocytic leukemia cells by CCL25 fused with PE38 toxin. Leuk Res 2011;35:1254–60CrossRefGoogle ScholarPubMed
26Mohle, R, Failenschmid, C, Bautz, F, Kanz, L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999;13:1954–59CrossRefGoogle Scholar
27Möhle, R, Schittenhelm, M, Failenschmid, C, Bautz, F, Kratz-Albers, K, Serve, H et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000;110:563–72CrossRefGoogle ScholarPubMed
28Arai, J, Yasukawa, M, Yakushijin, Y, Miyazaki, T, Fujita, S. Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol 2000;64:323–32CrossRefGoogle ScholarPubMed
29Singh, S, Singh, UP, Stiles, JK, Grizzle, WE, Lillard, JW Jr.Expression and functional role of CCR9 in prostate cancer migration and invasion. Clin Cancer Res 2004;24:8743–50CrossRefGoogle Scholar
30Heinrich, EL, Arrington, AK, Ko, ME, Luu, C, Lee, W, Lu, J et al. Paracrine activation of chemokine receptor CCR9 enhances the invasiveness of pancreatic cancer cells. Cancer Microenviron 2013;6:241–45CrossRefGoogle ScholarPubMed
31Fusi, A, Liu, Z, Kummerlen, V, Nonnemacher, A, Jeske, J, Keilholz, U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 2012;10:52–5CrossRefGoogle ScholarPubMed
32Johnson, EL, Singh, R, Singh, S, Johnson-Holiday, CM, Grizzle, WE, Partridge, EE et al. CCL25–CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol 2010;8:62–5CrossRefGoogle ScholarPubMed
33Johnson-Holiday, C, Singh, R, Johnson, E, Singh, S, Stockard, CR, Grizzle, WE et al. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 2011;38:1279–85Google Scholar
34Kuhnelt-Leddihn, L, Muller, H, Eisendle, K, Zelger, B, Weinlich, G. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10? Arch Dermatol Res 2012;304:185–93CrossRefGoogle ScholarPubMed